Open AccessRNA therapeutics for cardiovascular disease
Author(s) -
Christian Boada,
Roman Sukhovershin,
Roderic I. Pettigrew,
John P. Cooke
Publication year - 2021
Publication title -
current opinion in cardiology/current opinion in cardiology, with evaluated medline
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.826
H-Index - 78
eISSN - 1080-787X
pISSN - 0268-4705
DOI - 10.1097/hco.0000000000000850
Subject(s) - medicine , disease , rna , clinical trial , bioinformatics , computational biology , gene , biology , pathology , genetics
The development of mRNA vaccines against coronavirus disease 2019 has brought worldwide attention to the transformative potential of RNA-based therapeutics. The latter is essentially biological software that can be rapidly designed and generated, with an extensive catalog of applications. This review aims to highlight the mechanisms of action by which RNA-based drugs can affect specific gene targets and how RNA drugs can be employed to treat cardiovascular disease, with the focus on the therapeutics being evaluated in clinical trials. The recent advances in nanotechnology aiding the translation of such therapies into the clinic are also discussed.